NCCN Guidelines Insights: Cervical Cancer, Version 1.2020: Featured Updates to the NCCN Guidelines

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The NCCN Guidelines for Cervical Cancer provide recommendations for diagnostic workup, staging, and treatment of patients with the disease. These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to first- and second-line systemic therapy recommendations for patients with recurrent or metastatic disease, and emerging evidence on a new histopathologic classification system for HPV-related endocervical adenocarcinoma.

Related collections

Most cited references 13

Record: found
Abstract: not found
Article: not found

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

Hyun Cheol Chung, Willeke Ros, Jean-Pierre Delord … (2019)

0 comments Cited 372 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Helen Michael, Philip DiSaia, Larry J Copeland … (2017)

On Aug 14, 2014, the US Food and Drug Administration approved the antiangiogenesis drug bevacizumab for women with advanced cervical cancer on the basis of improved overall survival (OS) after the second interim analysis (in 2012) of 271 deaths in the Gynecologic Oncology Group (GOG) 240 trial. In this study, we report the prespecified final analysis of the primary objectives, OS and adverse events.

0 comments Cited 206 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.

Ryo Kitagawa, Noriyuki Katsumata, Taro Shibata … (2015)

In metastatic or recurrent cervical cancer, cisplatin-based chemotherapy is standard. The JCOG0505 randomized phase III trial evaluated the clinical benefits of carboplatin-based regimen.

0 comments Cited 113 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Title: Journal of the National Comprehensive Cancer Network

Publisher: Harborside Press, LLC

ISSN (Print): 1540-1405

ISSN (Electronic): 1540-1413

Publication date Created: June 2020

Publication date (Print): June 2020

Volume: 18

Issue: 6

Pages: 660-666

Affiliations

[1 ]1Memorial Sloan Kettering Cancer Center;

[2 ]2UC San Diego Moores Cancer Center;

[3 ]3Duke Cancer Institute;

[4 ]4University of Wisconsin Carbone Cancer Center;

[5 ]5Dana-Farber/Brigham and Women’s Cancer Center;

[6 ]6Moffitt Cancer Center;

[7 ]7Fox Chase Cancer Center;

[8 ]8The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

[9 ]9Vanderbilt-Ingram Cancer Center;

[10 ]10Yale Cancer Center/Smilow Cancer Hospital;

[11 ]11University of Colorado Cancer Center;

[12 ]12Roswell Park Comprehensive Cancer Center;

[13 ]13Huntsman Cancer Institute at the University of Utah;

[14 ]14Abramson Cancer Center at the University of Pennsylvania;

[15 ]15City of Hope National Medical Center;

[16 ]16O'Neal Comprehensive Cancer Center at UAB;

[17 ]17Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

[18 ]18Mayo Clinic Cancer Center;

[19 ]19Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

[20 ]20Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

[21 ]21The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

[22 ]22Fred & Pamela Buffett Cancer Center;

[23 ]23University of Michigan Rogel Cancer Center;

[24 ]24Massachusetts General Hospital Cancer Center;

[25 ]25St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;

[26 ]26UCSF Helen Diller Family Comprehensive Cancer Center;

[27 ]27Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

[28 ]28Patient Advocate; and

[29 ]29National Comprehensive Cancer Network

Article

DOI: 10.6004/jnccn.2020.0027

PubMed ID: 32502976

SO-VID: 517b5d5f-9776-405a-9ec2-e138a7a9bf2f

History

Data availability:

Comments

Comment on this article

scite_

Cited by 101

See all cited by

Most referenced authors 548

See all reference authors

NCCN Guidelines Insights: Cervical Cancer, Version 1.2020 : Featured Updates to the NCCN Guidelines

Read this article at

Abstract

Related collections

Preventive and Emergency Medicine Insights

Most cited references 13

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 342

Cited by 101

Most referenced authors 548